United Therapeutics

United Therapeutics, incorporated in 1996, is headquartered in Silver Spring, Maryland, USA. The company operates primarily in the pharmaceuticals segment, focusing on the development and commercialization of medications designed to meet the unmet medical needs of patients with chronic and life-threatening conditions. Alongside pharmaceuticals, United Therapeutics is also involved in biotechnology, concentrating on cardiopulmonary and infectious diseases, as well as organ transplant technology. The company's key brands and products consist of treatments for pulmonary arterial hypertension (PAH), such as Remodulin (treprostinil) Injection, Tyvaso (treprostinil) Inhalation Solution, Adcirca (tadalafil) tablets, and Orenitram (treprostinil) Extended-Release Tablets. Additionally, they offer Unituxin (dinutuximab) Injection for high-risk neuroblastoma in pediatric patients. United Therapeutics primarily markets its products within the United States, its largest market. Moreover, it has an international presence, distributing its products in other countries through various collaborations, distributorships, and licensing agreements. (Powered by AI)